Catalent Pharma Solutions and Supernus Pharmaceuticals have entered into an agreement where Catalent is the supplier of Trokendi XR extended release capsules for Supernus. Terms of the pact were not disclosed.
Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the U.S. market. Trokendi XR delivers an extended-release form of topiramate, one of the most effective anti-epilepsy drugs. Supernus developed Trokendi XR using its own advanced drug delivery technology and transferred its formulation to Catalent for commercial manufacturing.
“Supernus selected Catalent as our commercial supply partner based on their extensive experience in manufacturing extended release products, the longstanding relationship we have had with them, and a proven track record of high quality,” said Jack Khattar, chief executive officer, president and director of Supernus.
Barry Littlejohns, president of Catalent’s Advanced Delivery Technologies business, said, “We offer customers integrated solutions that include both proprietary drug delivery technologies and advanced supply solutions for oral controlled release development and commercial products. We are pleased to have been selected by Supernus to work on this unique epilepsy product.”